- Home
- CRDF vs USAS Comparison
CRDF vs USAS Comparison
Compare CRDF & USAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- USAS
- Stock Information
- Founded
- CRDF 1999
- USAS 1998
- Country
- CRDF United States
- USAS Canada
- Employees
- CRDF N/A
- USAS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- USAS Metal Mining
- Sector
- CRDF Health Care
- USAS Basic Materials
- Exchange
- CRDF Nasdaq
- USAS Nasdaq
- Market Cap
- CRDF 196.2M
- USAS 386.9M
- IPO Year
- CRDF N/A
- USAS N/A
- Fundamental
- Price
- CRDF $2.63
- USAS $0.59
- Analyst Decision
- CRDF Strong Buy
- USAS Strong Buy
- Analyst Count
- CRDF 4
- USAS 1
- Target Price
- CRDF $12.00
- USAS $1.00
- AVG Volume (30 Days)
- CRDF 1.1M
- USAS 1.5M
- Earning Date
- CRDF 05-20-2025
- USAS 05-19-2025
- Dividend Yield
- CRDF N/A
- USAS N/A
- EPS Growth
- CRDF N/A
- USAS N/A
- EPS
- CRDF N/A
- USAS N/A
- Revenue
- CRDF $683,000.00
- USAS $100,188,000.00
- Revenue This Year
- CRDF N/A
- USAS $45.78
- Revenue Next Year
- CRDF N/A
- USAS $17.98
- P/E Ratio
- CRDF N/A
- USAS N/A
- Revenue Growth
- CRDF 39.96
- USAS 18.02
- 52 Week Low
- CRDF $2.01
- USAS $0.21
- 52 Week High
- CRDF $5.64
- USAS $0.65
- Technical
- Relative Strength Index (RSI)
- CRDF 41.22
- USAS 52.55
- Support Level
- CRDF $2.42
- USAS $0.55
- Resistance Level
- CRDF $2.87
- USAS $0.64
- Average True Range (ATR)
- CRDF 0.18
- USAS 0.05
- MACD
- CRDF 0.01
- USAS -0.00
- Stochastic Oscillator
- CRDF 24.42
- USAS 60.67
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About USAS Americas Gold and Silver Corporation no par value
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.